MDxHealth (NASDAQ:MDXH) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

MDxHealth (NASDAQ:MDXH) issued its earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05), FiscalAI reports. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%.The firm had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million.

Here are the key takeaways from MDxHealth’s conference call:

• MDxHealth will discontinue its Resolve UTI business and shut the Plano lab, citing an increasingly uncertain reimbursement environment and a recent Novitas policy reversal.
• The company said Novitas is seeking up to $10.4 million in recoupments of historical Resolve claims, which MDxHealth is disputing through the Medicare appeals process.
• Q1 2026 revenue was $27.4 million as reported, or $23.9 million on a pro forma basis excluding Resolve, which management said represented 11% growth in the core prostate cancer business.
• Pro forma operating loss widened to $7.9 million from $4.7 million a year ago, while pro forma net loss was $9.4 million, reflecting the added impact of the ExoDx acquisition.
• Management reaffirmed its focus on prostate cancer diagnostics and raised 2026 revenue guidance for the core business to $110 million-$115 million, implying 20%-26% year-over-year growth.

MDxHealth Trading Down 49.5%

Shares of MDXH opened at $0.98 on Friday. MDxHealth has a 1-year low of $0.94 and a 1-year high of $5.33. The firm’s 50-day moving average price is $2.47 and its 200-day moving average price is $3.25. The firm has a market capitalization of $48.74 million, a price-to-earnings ratio of -1.47 and a beta of 1.60.

Trending Headlines about MDxHealth

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: Lake Street Capital cut its price target to $5.00 from $9.00, but reiterated a buy rating, suggesting meaningful upside from the current share price despite the reduced target. Lake Street Capital price target cut
• Positive Sentiment: BTIG Research also lowered its target to $4.00 from $7.00 while keeping a buy rating, indicating analysts still see recovery potential even after the earnings reset. BTIG Research price target cut
• Neutral Sentiment: MDxHealth reported first-quarter 2026 results, including revenue of $23.9 million and adjusted EPS of -$0.19, which investors are parsing for signs of operating improvement. Q1 2026 earnings report
• Negative Sentiment: The quarter missed Wall Street expectations on both profit and revenue, with EPS below estimates and sales well under consensus, reinforcing concerns about execution and growth momentum. Q1 2026 earnings miss
• Negative Sentiment: Management’s FY2026 revenue guidance of $110 million to $115 million came in below the market’s expectation of about $122.6 million, adding pressure to the stock after the earnings release. FY2026 guidance
• Negative Sentiment: William Blair downgraded MDxHealth from outperform to market perform, another sign that sentiment has cooled after the weak quarterly update. William Blair downgrade

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MDXH shares. TD Cowen reissued a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday. BTIG Research decreased their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. William Blair downgraded shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday. Lake Street Capital dropped their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, MDxHealth presently has an average rating of “Moderate Buy” and an average price target of $4.62.

Institutional Trading of MDxHealth

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Intesa Sanpaolo Wealth Management bought a new stake in MDxHealth during the 4th quarter valued at approximately $36,000. Lido Advisors LLC bought a new position in shares of MDxHealth in the 3rd quarter worth approximately $48,000. Citadel Advisors LLC raised its position in shares of MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock worth $228,000 after acquiring an additional 11,456 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth in the 3rd quarter valued at approximately $53,000. Finally, Squarepoint Ops LLC purchased a new position in shares of MDxHealth in the 4th quarter valued at approximately $51,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.